Ding, ZhijieAlshreef, AbualbishrFavaro, ElenaHoehn, DanielaSureda, AnnaDanilov, Alexey V.Thiruvengadam, Swetha KambhampatiLinton, KimCumings, KarenChirikov, ViktorMutebi, AlexChawla, Savreet BainsChhibber, AninditRivas Navarro, FernandoGonçalves, Felipe MarquesWang, Anthony2025-11-272025-11-272025-08-122473-9529https://hdl.handle.net/2445/224474This matching-adjusted indirect comparison evaluated the efficacy of epcoritamab vs standard of care (SOC), mosunetuzumab, or odronextamab, and assessed safety vs mosunetuzumab and odronextamab. Individual patient-level data from the EPCORE NHL-1 follicular lymphoma (FL) cohort for epcoritamab were used with pooled data from SCHOLAR-5 for SOC (mostly chemoimmunotherapy [CIT]), and aggregate data from GO29781 for mosunetuzumab and ELM-2 for odronextamab. Trial populations were match-adjusted using propensity score weights for key baseline characteristics. Compared with SOC/CIT, epcoritamab provided significantly higher response rates (overall response rate [ORR], 90.9% vs 56.8%; P < .001; complete response [CR] rate, 73.7% vs 32.0%; P < .001). Epcoritamab showed numerically higher ORR (90.9% vs 80.0%; P = .067) and CR rate (72.8% vs 60.0%; P = .159) vs mosunetuzumab. Epcoritamab provided significantly higher ORR (91.5% vs 80.5%; P = .026) and numerically lower CR rate (67.5% vs 73.4%; P = .428) vs odronextamab. Epcoritamab did not have any grade ≥3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS; any grade) events compared with CRS (grade ≥3) in 2.2% and 3.9% and ICANS in 4.4% and 0.8% of patients treated with mosunetuzumab and odronextamab, respectively (P < .001). In addition to being a convenient subcutaneous option, epcoritamab showed significantly superior response rates and survival outcomes vs SOC/CIT among patients with relapsed or refractory FL after ≥2 systemic therapies. Epcoritamab also exhibited clinically relevant, numerically higher ORRs and demonstrated improved safety for CRS (grade ≥3) and ICANS vs mosunetuzumab or odronextamab.12 p.application/pdfengcc by-nc-nd (c) Ding, Zhijie et al., 2025https://creativecommons.org/licenses/by-nc-nd/4.0/Anticossos monoclonalsMedicaments antineoplàsticsLimfomesMonoclonal antibodiesAntineoplastic agentsLymphomasinfo:eu-repo/semantics/article7619402025-11-27info:eu-repo/semantics/openAccess40472301